^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DDR enhancer

    Related drugs:
    6ms
    TOPOLOGY: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Institut Curie | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Aug 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    PLX038
    10ms
    POP-ART: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=92, Recruiting, Institut Curie | Trial primary completion date: Sep 2027 --> Sep 2028
    Trial primary completion date
    |
    PLX038 • tuvusertib (M1774)
    10ms
    POP-ART: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=92, Recruiting, Institut Curie | Not yet recruiting --> Recruiting | Trial completion date: Feb 2029 --> Sep 2029 | Initiation date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Sep 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    PLX038 • tuvusertib (M1774)
    over1year
    PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Mayo Clinic | Trial completion date: Feb 2025 --> Dec 2031 | Trial primary completion date: Feb 2025 --> May 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    PLX038 • firtecan pegol (PEG-SN38)
    over1year
    TOPOLOGY: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Institut Curie | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PLX038
    over1year
    POP-ART: A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=92, Not yet recruiting, Institut Curie
    New P1 trial • Combination therapy • Metastases
    |
    PLX038 • tuvusertib (M1774)
    almost2years
    PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (clinicaltrials.gov)
    P1/2, N=120, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    PLX038
    almost2years
    PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Mayo Clinic | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial primary completion date • Metastases
    |
    ABCG2 expression
    |
    PLX038 • firtecan pegol (PEG-SN38)
    2years
    TOPOLOGY: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Institut Curie
    New P2 trial
    |
    PLX038
    2years
    PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    PLX038
    2years
    PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Mayo Clinic | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    ABCG2 expression
    |
    PLX038 • firtecan pegol (PEG-SN38)
    2years
    PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=43, Suspended, Mayo Clinic | N=31 --> 43
    Enrollment change • Metastases
    |
    ABCG2 expression
    |
    PLX038 • firtecan pegol (PEG-SN38)